ArticleBioorganic & medicinal chemistry letters2025
Design, synthesis and evaluation of clickable photoaffinity probes for nuclear lamins.
Article in Bioorganic & medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Clofibric Acid as a Synoviolin (SYVN1) Ligand for Proteolysis-Targeting Chimera (PROTAC) Development.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nuclear lamins are type V intermediate filament proteins to support the mechanical stability of mammalian cell nucleus. They also participate in various signaling activities in the cells. We recently discovered substituted pyrroloquinazoline LBL1 as the first small molecule to directly target nuclear lamins despite their poor druggability. Based on LBL1, a clickable photoaffinity probe LBL1-PCF was designed to identify lamin-interactors in native cells. In this work, we designed and synthesized a series of clickable photoaffinity probes to evaluate the structure-activity relationships for lamin labeling. Appending an azidopropyl group to the pyrroloquinazoline core at N-7 was well-tolerated without affecting the labeling EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.